Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation.
about
Immunomodulation in stable renal transplant recipients with concomitant tacrolimus and sirolimus therapySystemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitorsPotential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disordersTherapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity.Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial.Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects.The potential role of rapamycin in pediatric transplantation as observed from adult studies.Calcineurin-inhibitors in renal transplantation. Too precious to be abandoned.Sirolimus: continuing the evolution of transplant immunosuppression.Immunologic considerations in composite tissue transplantation: overview.Immunosuppressive agents in transplantation: mechanisms of action and current anti-rejection strategies.mTOR inhibitors: an overview.New developments in the prophylaxis and treatment of graft versus host disease.Gastrointestinal infectious disease complications following transplantation and their differentiation from immunosuppressant-induced gastrointestinal toxicities.Sirolimus: a comprehensive review.Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model.Cardiovascular toxicities of immunosuppressive agents.Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantationThe effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer.Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent.Clinical application of sirolimus in renal transplantation: an update.Hand transplantation. A future clinical option?Nanomedicines in renal transplant rejection--focus on sirolimusToxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment.Impact of mTOR-I on fertility and pregnancy: state of the art and review of the literature.Immunostimulatory activity of lifespan-extending agents.mTOR inhibitors and renal allograft: Yin and Yang.Chronic renal insufficiency in heart transplant recipients: risk factors and management options.Early steroid withdrawal results in improved patient and graft survival and lower risk of post-transplant cardiovascular risk profiles: A single-center 10-year experience.TGF-β1 mediates sirolimus and cyclosporine A-induced alteration of barrier function in renal epithelial cells via a noncanonical ERK1/2 signaling pathway.Compared effect of immunosuppressive drugs cyclosporine A and rapamycin on cholesterol homeostasis key enzymes CYP27A1 and HMG-CoA reductase.Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus.Effects of calcineurin inhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipients.Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients.Symptomatic lymphoceles after kidney transplantation - multivariate analysis of risk factors and outcome after laparoscopic fenestration.Repeat renal allografts treated with sirolimus, cyclosporine, anti-thymocyte globulin induction and continuous steroids achieve similar immunosuppressive efficacy as primary transplants.Sirolimus improves the two-year outcome of renal allografts in African-American patients.Care of the kidney transplant recipient. Vigilant monitoring creates the best outcome.Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation.A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus.
P2860
Q24799790-97CB2EF1-8A25-448E-9640-053C6D24710BQ26823023-29F949DB-5346-4743-AE06-995FD937B69FQ28067037-C681D945-94BE-4C7E-A683-C33C1140407AQ33332141-A1F11D67-3B94-4749-AD2E-968AEBBB706DQ33338797-253C0267-49F9-4A49-A628-76AE887B76E5Q33393707-48D04011-16BF-42DE-8F30-F6705D9D7C0CQ33732940-4EB1D3DF-5E4A-4250-8582-A6C1CD7C29DCQ34025909-ADC92E7D-EAE1-4279-A373-4B58FE47BDCFQ34028674-42AA373A-50A0-40EF-814B-AB8CEC39EC19Q34126611-2792E4F2-326A-4B1A-ADC9-429FBFFC3526Q34126617-5D165D09-6FF4-4FB5-A73C-9341F13BFB78Q34302240-AF8EF991-17C1-472A-AD3E-7FE6BB5B7817Q34388580-E58FFAEA-7334-4CF6-8CBF-D94448228F21Q34485472-F1B8FC86-DB87-4A6C-AA24-65764832FA4CQ34515537-1E748D63-745A-4CFE-8A7A-288F15707E05Q34740561-E5BDE35A-A458-4B21-9A35-093166E49212Q34976738-60A865D7-0544-461E-8891-4D6431BD1E0FQ35184589-1C6BBAE6-D82B-4BE8-9488-B6949D052622Q35223564-F364913A-4CE1-4C2F-A71D-C82015BEE066Q35758328-084AF619-041E-49E4-875F-DF5653E8BBE7Q36054093-B56188DF-51BD-4D96-A8E8-ADFA47C226C7Q36078907-21C2D6D3-5418-4567-8F4D-47B475D49929Q36920414-44B4ED28-6D65-4594-8D68-C5C40EE03AA4Q37873950-24606DCE-C552-46D2-BA93-3CC4B9A03702Q38131036-BA0E7570-8BE4-4D85-9501-151BA674086FQ38175673-24A9B16E-9157-4BFF-BAA6-7931E359BB31Q38209973-5402917E-ED44-4940-9378-E7B9D54BE737Q38240994-379FAEF1-A282-4A62-A9AD-C38709CBC010Q39152770-CA0833AB-CBF0-4E4C-AD93-F5BE323647A0Q39481525-BB84EB5C-5245-4FE9-9343-12E427CE0322Q40129780-198CFFB1-6E86-47CA-AC9D-59953FD881F9Q40396910-6BE5B0B0-0FF6-4060-BBFD-B191282D5BFCQ42656832-B2895343-C8F7-472C-B6F9-05CC702AD836Q42680562-255C89D2-10D4-4BF9-B6F2-0729075832D5Q43283119-C88D9691-AA14-455E-A3CF-87579F60C46EQ43289023-843A0A2D-7C2B-44E1-AFA6-EB6E2B001B28Q43493492-612E0D58-42AE-4687-8AE6-B35B61F59458Q44165376-97580EC3-F01A-4B67-8E77-C46694357605Q44860714-16367FEE-3AD3-47B1-A6A1-AB2392AFFEC0Q45214571-F1BE062D-6835-4408-BE8E-4E3E6D5D9C71
P2860
Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Immunosuppressive effects and ...... men for renal transplantation.
@en
Immunosuppressive effects and ...... men for renal transplantation.
@nl
type
label
Immunosuppressive effects and ...... men for renal transplantation.
@en
Immunosuppressive effects and ...... men for renal transplantation.
@nl
prefLabel
Immunosuppressive effects and ...... men for renal transplantation.
@en
Immunosuppressive effects and ...... men for renal transplantation.
@nl
P2093
P1433
P1476
Immunosuppressive effects and ...... men for renal transplantation.
@en
P2093
Meier-Kriesche HU
Podbielski J
Van Buren CT
P304
P356
10.1097/00007890-199810270-00013
P577
1998-10-01T00:00:00Z